LEAP-Kazakhstan 2026

Survey Variable Manual

Lenacapavir Evaluation of Acceptability and Preferences Study. An anonymous online survey of key populations in Kazakhstan, 16 June to 31 August 2026.

Release dataset version 1.0

Manual version 1.1, 28 October 2026

Principal investigators

Nikolay Lunchenkov, Sairankul Kassymbekova, Assel Terlikbayeva

Please cite this manual as

LEAP-Kazakhstan Study Team (2026). LEAP-Kazakhstan 2026 Survey Variable Manual, version 1.1. Technical University of Munich.

Publications using the data must also cite the LEAP-Kazakhstan study protocol and must offer the three principal investigators the opportunity to take part as co-authors.

Contact: nikolay.lunchenkov@tum.de

Contents

1. Introduction **3**
1.1 Survey languages and recruitment 3
1.2 Data files and access 3
1.3 Variable names 3
1.4 How to read the questionnaire entries 3
2. Cases Submitted and Qualifying Cases **4**
2.1 Quality exclusions 4
3. Questionnaire Content: Conceptual Overview **5**
4. Technical Notes on the Questionnaire **6**
4.1 Irregular variable names 6
4.2 Non-consecutive response codes 6
4.3 Direction of scales 6
4.4 Question type deviations 6
4.5 Piped text 6
4.6 Variables withheld from the release file 7
5. Data Cleaning and Quality Flags **8**
6. Missing Data, Standard Response Sets and Definitions **9**
6.1 Missing-data codes 9
6.2 Standard response sets 9
6.3 Multiple-response questions 9
6.4 Definitions 10
7. Case Variables **11**
8. The Questionnaire **12**
8.1 Block A. Screening and eligibility 12
8.2 Block B. Demographics 13
8.3 Block C. HIV risk behaviours and prevention 15
8.4 Block D. Educational materials about lenacapavir 19
8.5 Block F. Acceptability and willingness to use 20
8.6 Block G. Perceived benefits 22
8.7 Block H. Concerns and barriers 23
8.8 Block I. Administration preferences 24
8.9 Block J. Healthcare experiences and stigma 26
8.10 Block K. Population-specific questions 27
8.11 Block K2. Mental health 35
8.12 Block K-8. Perceptions of PrEP 35
8.13 Block L. Decision-making and information 38
8.14 Block M. Final questions 39
9. Derived Variables **40**
10. City and Region Response Set (A3) **42**
11. Routing Summary **43**

1. Introduction

LEAP-Kazakhstan is a mixed-methods study of the acceptability of twice-yearly injectable lenacapavir for HIV prevention among key populations in Kazakhstan. This manual describes the quantitative strand, an anonymous online survey hosted on Qualtrics. It documents every variable in the release dataset, the routing that determined which respondents saw which question, the coding of missing data, and the variables derived by the study team.

The study is led by ECOM, the Eurasian Coalition on Health, Rights, Gender and Sexual Diversity (Estonia), in partnership with the Technical University of Munich (Germany), the Kazakh Scientific Centre of Dermatology and Infectious Diseases, the Global Health Research Center of Central Asia and Al-Farabi Kazakh National University (Kazakhstan). It is funded by the WEEPI Foundation (Switzerland). The survey was approved by the Ethics Committee of Al-Farabi Kazakh National University (IRB-A1949, 26 February 2026) and the Ethics Committee of the Technical University of Munich (2026-192-S-KH, 2 April 2026).

1.1 Survey languages and recruitment

The questionnaire was offered in Russian, Kazakh and English. The language used by each respondent is recorded in LANGUAGE. Respondents were recruited by peer outreach workers in several cities and through online community channels, peer networks and dating applications. Each recruiter or channel had its own survey link. Links are identified in the data by an anonymised code (RECRUIT_LINK). Respondents were told that the survey would take about 20 to 25 minutes.

1.2 Data files and access

The full release dataset contains 969 respondents and 260 variables. The full dataset is not shared. Approved users receive the variables approved in their concept note, drawn from this file, as an SPSS file (LEAP_Kazakhstan_2026_release_v1.sav) with variable labels, value labels and declared missing values, and as a comma-separated file (LEAP_Kazakhstan_2026_release_v1.csv) with the same numeric codes. Data are released under a data transfer agreement after approval of a concept note by the Technical University of Munich.

1.3 Variable names

Variable names are those assigned by Qualtrics and are identical to the item numbers in the questionnaire wherever possible (for example A1, C3a, F2). Items with several variables add a suffix. For multiple-response questions the suffix is the Qualtrics choice code (for example C6_8). For grids it is the position of the row (for example F5_3 is the third row of F5). Choice codes are not always consecutive, because codes were retained when options were added or removed during questionnaire development. Hyphens in item numbers become underscores in variable names (item K-MSM1 is variable K_MSM1). A small number of variables carry irregular names. They are listed in Section 4.1. Variables created by the study team are written in capitals with a descriptive name (for example KP_GROUP, PHQ4).

1.4 How to read the questionnaire entries

- A routing condition in square brackets above a question gives the condition under which it was displayed. Questions without a routing line were shown to all respondents who reached them.
- The entry heading gives the item number and the full question text as shown to respondents (English version).
- Single-choice questions list each response code with its label. The missing-data codes that can occur for the question are listed underneath in grey.
- Multiple-response questions list one variable per option. Each option is coded 1 if selected and 0 if not selected.
- Grid questions list one variable per item. All items of a grid share the response codes given under the table.
- The manual describes the structure of the data only. It contains no frequencies or other results.
- A dagger (†) marks a response option or grid row that was displayed only to some respondents.

2. Cases Submitted and Qualifying Cases

Eligibility followed the screening questions of the survey. Respondents who did not consent, were under 18, reported a positive HIV test result, lived outside Kazakhstan or did not belong to any of the four key populations were taken to the end of the survey. Table 2.1 shows the flow from the raw export to the release sample.

Step	Remaining	Removed
Records in the Qualtrics export	1,803	
Consented (IC3=1)	1,548	255
Aged 18 or older (A1)	1,514	34
Not known HIV-positive (A2)	1,275	239
Living in Kazakhstan (A3)	1,244	31
At least one key population (A4)	1,005	239
Final sample after quality exclusions	**969**	**36**

Table 2.1. Case flow.

2.1 Quality exclusions

A lenient cleaning strategy was used to keep as much data as possible. Of the 1,005 eligible respondents, 36 were excluded by the following rules, applied in order.

Rule	Excluded
R1. Survey finished in under 6 minutes	31
R2. Survey not finished and answered at click-through pace	0
R3. No substantive answer after the screening questions	5

Partial responses were retained. Respondents who left the survey before the end are included with the questions they did not reach coded -2 (Section 6.1).

3. Questionnaire Content: Conceptual Overview

The questionnaire has fourteen blocks. Block D presented standardised information about lenacapavir before the questions on its acceptability, benefits, concerns and delivery (blocks F to M). Only C2a, which asks whether respondents had heard of injectable lenacapavir, came before block D. All respondents who reached block D saw the same text. Table 3.1 summarises the content of each block and who was eligible to see it.

Block	Title	Content	Shown to	Vars
A	Screening and eligibility	Age, HIV status, city of residence, key population, primary identity	All	9
B	Demographics	Gender identity, sex assigned at birth, education, employment, income, housing, relationship status	All	11
C	HIV risk and prevention	HIV testing, PrEP awareness, current and past PrEP use, reasons for stopping, condom use, STI testing and diagnoses	All, with PrEP items routed by C2, C3 and C3a	44
D	Information on lenacapavir	Standardised text on how lenacapavir works, efficacy in the PURPOSE trials, administration schedule, side effects and key facts. No variables.	All	0
F	Acceptability and willingness	Acceptability, willingness, willingness to pay with and without subsidy, likelihood of use, preferred PrEP option, decision factors	All	15
G	Perceived benefits	Importance of eight potential benefits and the single most important one	All	9
H	Concerns and barriers	Concern about eight potential problems, the main concern, reassurance from oral bridging	All	10
I	Administration preferences	Preferred site, provider, scheduling and reminders, features of a safe location	All	12
J	Healthcare experiences and stigma	Trust in providers, avoidance of care, enacted stigma by key population, worry about stigma	All, J3 rows by key population	18
K	Population-specific questions	Modules for GBMSM (sexual orientation, partners, apps, chemsex, privacy), people who use drugs, sex workers and transgender people	By key population (Section 11)	47
K2	Mental health	PHQ-4 (GAD-2 and PHQ-2)	All	4
K-8	Perceptions of PrEP	Facilitators of and barriers to oral PrEP use	GBMSM (8.1) and current or past PrEP users (8.2, 8.3)	41
L	Decision-making and information	Information needs, preferred sources, people consulted	All	18
M	Final questions	Interest in learning more about lenacapavir	All	1

Table 3.1. Questionnaire blocks. Vars gives the number of item variables in the release file.

4. Technical Notes on the Questionnaire

4.1 Irregular variable names

Variable	Explanation
A_7	Condom use in the past 6 months (item C7). The item label was typed with a Cyrillic letter and Qualtrics exported it as A_7.
STI2_	STI diagnosis in the past 12 months (item STI2). The name carries a trailing underscore.
Q105, Q108	Chemsex screener and use of dating apps in the GBMSM module. Internal Qualtrics names.
Q110, Q111, Q112	Second pages of the grids H1, F5 and G1. Each grid was split over two screens of four items.
K_PFB8.1__..., K_PFB8.2__..., K_PFB8.3_...	Items of block K-8. The names contain dots and double underscores. Stata does not allow dots in variable names, so check the names after conversion.

4.2 Non-consecutive response codes

Many single-choice items keep the Qualtrics choice codes, which are not consecutive (for example 1, 4, 5, 6, 7 for a five-point scale). Affected items are A3, F6, H3, I1, I4, I5, J2, J4, K-MSM1, K-MSM2, K-MSM4, K-MSM6, K-MSM7, K-MSM8, K-PWUD2 to K-PWUD5, K-SW2 to K-SW5, K-TW1 to K-TW5, K-PFB8.1 Q11 and M2. In the ordinal items the order of the codes follows the order of the scale, except in K_MSM6 (Section 4.3). In the nominal items I1 and K-PFB8.1 Q11 the codes do not follow the order in which the options were displayed. Recode to consecutive values before treating any of these items as an ordinal score. In K_TW2, code 8 (Not applicable, not taking hormones) is not part of the concern scale.

4.3 Direction of scales

- The direction of single-choice scales differs between items, so check the code list of each item. F1, F2 and M2 run from the most favourable answer (1 = very acceptable, very willing, yes definitely) to the least favourable. F2a and F2b start with 1 = would not use it unless it is free, followed by ascending price bands. K_PWUD2, K_PWUD4, K_PWUD5 and K_SW4 run from the highest frequency, comfort, confidence or flexibility to the lowest. J4, K_MSM7, K_SW5, K_TW2 and K_TW4 run from the lowest level of worry, importance or concern to the highest.
- Grid items (F5, Q111, G1, Q112, H1, Q110, J1, K2-2, K-PFB8.1, K-PFB8.2) are coded in ascending order, with 1 as the lowest level of importance, concern, agreement, frequency or barrier.
- K_MSM6 is reverse coded relative to similar items: 1 = Extremely important and 7 = Not at all important.

4.4 Question type deviations

- STI3 is worded as select-all-that-apply but was programmed as a single-choice item.
- I3 is worded as a single question but was programmed as select-all-that-apply.
- L3 is worded as a single question but was programmed as select-all-that-apply.
- In K-MSM5 the exclusive option None of the above was not exported. Respondents who chose it cannot be distinguished from those who skipped the question and are coded -9.
- K-PWUD4, K-PWUD5 and K-SW4 sit in the population-specific block but had no display condition. They were shown to all respondents who reached them.
- Options that are logically exclusive were not programmed as exclusive in C2a (C2a_5, not heard of any specific type), STI4 (STI4_8, I test regularly), I3 (I3_7, no preference), K-PFB8.3 Q25 (K_PFB8.3_Q25_41, nothing would prevent me) and L3 (L3_7, my personal decision). Some respondents selected them together with other options.

4.5 Piped text

C5 and the K-8 block insert the PrEP type chosen at C3a (daily oral PrEP or on-demand PrEP) into the question text. Respondents without an answer at C3a saw the word PrEP. These are past PrEP users in K-PFB8.2 and K-PFB8.3, and

GBMSM who were not current users in K-PFB8.1. Several K-8 rows and choices were specific to one PrEP type and are marked with a dagger in Section 8.

4.6 Variables withheld from the release file

Withheld	Reason
IP address, location, recipient fields, Qualtrics response ID	Direct or indirect identifiers. A sequential LEAP_ID replaces the response ID.
End date, recorded date, start time of day	Precise timestamps. START_DATE is given to the day.
STI2a_9_TEXT, K_MSM1_6_TEXT, K_MSM3_11_TEXT, K_PWUD1_8_TEXT	Free-text answers may contain identifying detail. Available on request after review.
Recruiter names	Replaced by the anonymised code RECRUIT_LINK.
IC3, Status, DistributionChannel	Constant in the release sample (all consented, all anonymous links).

Qualtrics metadata that are retained are renamed and described as case variables in Section 7: StartDate as START_DATE, Duration as DURATION_MIN, Progress as PROGRESS, Finished as FINISHED, UserLanguage as LANGUAGE, Q_RecaptchaScore as RECAPTCHA and the recruitment link as RECRUIT_LINK.

5. Data Cleaning and Quality Flags

No answers were edited, recoded into other categories or imputed. The only changes to the raw responses are the missing-data codes described in Section 6.1, the 0 and 1 coding of multiple-response options, and the removal of the variables listed in Section 4.6.

Several indicators of response quality were computed but not used for exclusion, because peer outreach workers often helped participants on shared devices and because partial responses still carry useful information. They are provided as flags so that users can run sensitivity analyses.

Variable	Definition (0 = No, 1 = Yes)
FLAG_INCOMPLETE	Survey not submitted to the end, or progress below 100%
FLAG_LOW_RECAPTCHA	Qualtrics reCAPTCHA score below 0.5. Coded 0 when no score was recorded.
FLAG_SHARED_IP	Same IP address as at least one other eligible response. Expected with shared outreach devices.
FLAG_SPEEDER	Finished in less than one third of the median duration of finished eligible responses (threshold about 6 minutes)

6. Missing Data, Standard Response Sets and Definitions

6.1 Missing-data codes

Every item variable distinguishes three kinds of missing data. The codes are declared as user-missing values in the SPSS file. In the CSV file they appear as numbers and must be set to missing before analysis.

Code	Meaning	Assigned when
-1	Not shown	The routing or display logic did not show the question, grid row or response option to this respondent.
-2	Not reached	The question would have been shown, but the respondent left the survey before reaching it. Assigned to every question after the last question the respondent answered.
-9	Not answered	The question was shown and reached but left blank. Skipping questions was allowed throughout.

For multiple-response questions, options are coded 1 (selected) or 0 (not selected) when the respondent selected at least one option. When no option was selected, all options receive the same missing-data code. An option that was not displayed to a respondent is coded -1 even when other options were answered.

When a routing condition depends on a question that the respondent did not answer or did not reach, the dependent question is coded -1. For example, a respondent who left the survey before C3 is coded -2 on C3 and -1 on C3a.

6.2 Standard response sets

Importance response set used by F5, Q111, G1, Q112, K-PFB8.1

1 = Not at all important 2 = Slightly important 3 = Moderately important 4 = Very important 5 = Extremely important

Concern response set used by H1, Q110

1 = Not at all concerned 2 = Slightly concerned 3 = Moderately concerned 4 = Very concerned 5 = Extremely concerned

Agreement response set used by J1

1 = Strongly disagree 2 = Disagree 3 = Neither agree nor disagree 4 = Agree 5 = Strongly agree

Barrier response set used by K-PFB8.2

1 = Not at all a barrier 2 = Slightly a barrier 3 = Moderately a barrier 4 = Very much a barrier 5 = Extremely a barrier

PHQ-4 frequency response set used by K2-2

1 = Not at all 2 = Several days 3 = More than half the days 4 = Nearly every day

Experience response set used by J3

1 = Yes 2 = No 3 = Prefer not to answer

6.3 Multiple-response questions

Question	Shown to	Options
A4	All	5
B4	All	5
C2a	C2=1 or C2=3 (heard of PrEP or not sure)	5
C6	C3=2 (used PrEP in the past)	12
STI2a	STI2_=1 (diagnosed with an STI in the past 12 months)	9
STI4	All	8
I2	All	5
I3	All	4
K-MSM3	Q105=1 or Q105=3 (chemsex yes, or unsure what the term means)	9

Question	Shown to	Options
K-MSM5	Q105=1 or Q105=3	6
K-PWUD1	A4_2=1 (people who use drugs)	7
K-PWUD1b	A4_2=1	4
K-PFB8.3 Q25	C3=1 or C3=2	14
L1	All	8
L2	All	5
L3	All	5

6.4 Definitions

Key populations. Self-identified at A4 as gay, bisexual or other man who has sex with men (GBMSM), person who uses drugs (synthetic stimulants, opioids or other non-cannabis psychoactive substances in the past 12 months), sex worker (exchanging sex for money, goods or services), or transgender person.

PrEP. Pre-exposure prophylaxis, medication taken to prevent HIV. Daily oral PrEP, on-demand (2-1-1) oral PrEP, injectable cabotegravir every 2 months and injectable lenacapavir every 6 months were named in the questionnaire.

Lenacapavir. Twice-yearly subcutaneous injectable PrEP. It was not available in Kazakhstan at the time of the survey. All questions about lenacapavir are hypothetical. Apart from C2a (awareness), they follow the information text in block D.

Chemsex. Defined at Q105 as the intentional use of drugs such as mephedrone, Alpha-PHP or GHB/GBL to enhance or prolong sex, often in longer sessions or with multiple partners. Respondents who were unsure what the term means (Q105=3) were routed to the chemsex follow-up questions.

7. Case Variables

Case variables describe the response rather than the respondent's answers.

Variable	Description	Values
LEAP_ID	Respondent serial number, ordered by start date	1 to 969
START_DATE	Date the survey was started	YYYY-MM-DD, within the fieldwork period
DURATION_MIN	Minutes from start to last activity	Minutes, one decimal
PROGRESS	Qualtrics progress indicator	Percent, 0 to 100
FINISHED	Survey submitted to the end	0 = No, 1 = Yes
LANGUAGE	Survey language	1 = Russian, 2 = Kazakh, 3 = English
RECAPTCHA	Qualtrics reCAPTCHA score	0 to 1, two decimals. Blank (system-missing) when Qualtrics recorded no score
RECRUIT_LINK	Recruitment link, anonymised	1 to 12; -9 = Not recorded

Quality flags (FLAG_...) are described in Section 5.

8. The Questionnaire

Questions are listed in the order in which they were presented. The informed consent text and block D contain no variables and are summarised in their place.

8.1 Block A. Screening and eligibility

A1. How old are you?

Variable: A1 Single choice

Code	Response
1	Under 18 years old
2	18–24 years old
3	25–34 years old
4	35–44 years old
5	45–54 years old
6	55 years or older

Note. *Screener. Code 1 (under 18) ended the survey.*

A2. What is your current HIV status?

Variable: A2 Single choice

Code	Response
1	I am HIV-negative (last test is negative)
2	I am HIV-positive (last test is tested positive)
3	I never tested for HIV
4	I am not sure

Note. *Screener. Code 2 (HIV-positive) ended the survey.*

A3. In which city do you currently live? (Select from the list below)

Variable: A3 Single choice. Response set in Section 10.

Note. *Screener. Code 26 (outside Kazakhstan) ended the survey.*

A4. Which of the following best describes you? (Select all that apply)

Variables: A4_1 to A4_5 (5) Multiple response

Variable	Option
A4_1	Gay, bisexual, or other man who has sex with men (GBMSM)
A4_2	Person who uses drugs (used synthetic stimulants/bath salts, opioids, or other non-cannabis psychoactive substances in the past 12 months)
A4_3	Sex worker (exchange sex for money, goods, or services)
A4_4	Transgender person
A4_5	None of the above

Each option: 1 = Selected, 0 = Not selected. Screener question, no missing values.

Note. *Screener. A4_5 (None of the above) was exclusive and ended the survey, so it is 0 for every qualifying respondent.*

[If two or more key populations were selected at A4]

A5. Which of the groups you selected best describes your primary identity? (Select one)

Variable: A5 Single choice

Code	Response
1	Gay, bisexual, or other man who has sex with men (GBMSM)
2	Person who uses drugs (used synthetic stimulants/bath salts, opioids, or other non-cannabis psychoactive substances in the past 12 months)
3	Sex worker (exchange sex for money, goods, or services)
4	Transgender person
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

Note. *Only the groups selected at A4 were offered as answer options.*

8.2 Block B. Demographics

B1. What is your gender identity?

Variable: B1 Single choice

Code	Response
1	Man
2	Woman
3	Transgender woman
4	Transgender man
5	Non-binary
-2	*Not reached*
-9	*Not answered*

B2. What sex were you assigned at birth?

Variable: B2 Single choice

Code	Response
1	Male
2	Female
3	Intersex
-2	*Not reached*
-9	*Not answered*

B3. What is the highest level of education you have completed?

Variable: B3 Single choice

Code	Response
1	Primary school or less
2	Secondary school (incomplete)
3	Secondary school (complete)

Code	Response
4	Vocational/technical training
5	Some university
6	University degree or higher
-2	*Not reached*
-9	*Not answered*

B4. What is your current employment status? (Select all that apply)

Variables: B4_1 to B4_5 (5) Multiple response

Variable	Option
B4_1	Employed (full-time or part-time)
B4_2	Self-employed
B4_3	Unemployed
B4_4	Student
B4_5	Retired or unable to work

Each option: 1 = Selected, 0 = Not selected. If no option was selected, all options carry the same missing code (-2 = Not reached, -9 = Not answered).

B5. What is your approximate monthly income?

Variable: B5 Single choice

Code	Response
1	Less than 100,000 KZT
2	100,000–200,000 KZT
3	200,001–300,000 KZT
4	300,001–500,000 KZT
5	More than 500,000 KZT
-2	*Not reached*
-9	*Not answered*

B6. What is your current housing situation?

Variable: B6 Single choice

Code	Response
1	I own my home
2	I rent my own apartment or house (alone or with a partner)
3	I rent shared housing with roommates or flatmates
4	I live with my family or relatives
5	My housing is temporary or unstable (e.g., staying with friends short-term, hostels, no fixed place)
-2	*Not reached*
-9	*Not answered*

B7. What is your relationship status?

Variable: B7 Single choice

Code	Response
1	Single, not currently dating
2	Dating casually or seeing people without a steady partner
3	In one steady relationship (monogamous), not legally registered
4	In one steady relationship (open or non-monogamous), not legally registered
5	In more than one steady relationship (polyamorous)
6	Married or in a legally registered partnership
7	Separated or divorced
8	Widowed
-2	*Not reached*
-9	*Not answered*

8.3 Block C. HIV risk behaviours and prevention

C1. When was your last HIV test?

Variable: C1 Single choice

Code	Response
1	Within the past 6 months
2	7–12 months ago
3	More than 1 year ago
4	I never tested for HIV
5	I don’t remember
-2	*Not reached*
-9	*Not answered*

C2. Have you ever heard of PrEP (pre-exposure prophylaxis) — medication taken to prevent HIV?

Variable: C2 Single choice

Code	Response
1	Yes
2	No
3	Not sure
-2	*Not reached*
-9	*Not answered*

[If C2=1 or C2=3 (heard of PrEP or not sure)]

C2a. Which types of PrEP have you heard of? (Select all that apply)

Variables: C2a_1 to C2a_5 (5) Multiple response

Variable	Option
C2a_1	Daily oral PrEP (a pill taken every day)
C2a_2	On-demand PrEP (pills taken around the time of sex, also known as 2-1-1 dosing)

Variable	Option
C2a_3	Injectable PrEP with cabotegravir (CAB-LA) (an injection given every 2 months)
C2a_4	Injectable PrEP with lenacapavir (LEN-LA) (an injection given every 6 months)
C2a_5	I have not heard of any specific types

Each option: 1 = Selected, 0 = Not selected. If no option was selected, all options carry the same missing code (-1 = Not shown (routing), -2 = Not reached, -9 = Not answered).

C3. Are you currently using PrEP?

Variable: C3 Single choice

Code	Response
1	Yes, I am currently using PrEP
2	No, but I have used PrEP in the past
3	No, never used PrEP
-2	*Not reached*
-9	*Not answered*

[If C3=1 (currently using PrEP)]

C3a. Which type of PrEP are you currently using?

Variable: C3a Single choice

Code	Response
1	Daily oral PrEP
2	On-demand PrEP
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

[If C3=1 or C3=2 (current or past PrEP use)]

C4. How long have you been taking PrEP?

Variable: C4 Single choice

Code	Response
1	Less than 6 months
2	6–12 months
3	1–2 years
4	More than 2 years
5	More than 5 years
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

Note. *Categories 4 (More than 2 years) and 5 (More than 5 years) overlap as worded. Past users (C3=2) answered the same present-tense wording.*

[If C3a=1 or C3a=2]

C5. How difficult is it for you to remember to take <PrEP type from C3a>?

Variable: C5 Single choice

Code	Response
1	Very easy
2	Somewhat easy
3	Neither easy nor difficult
4	Somewhat difficult
5	Very difficult
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

Note. *Question text pipes in the PrEP type selected at C3a.*

[If C3=2 (used PrEP in the past)]

C6. Why did you stop taking PrEP? (Please select all that apply)

Variables: C6_1 to C6_13 (12) Multiple response

Variable	Option
C6_1	I experienced side effects
C6_2	I was worried about long-term effects on my health
C6_3	It was too difficult to remember to take pills every day
C6_4	I did not like taking medication every day
C6_5	I could not afford it
C6_6	I had difficulty accessing PrEP services because of documentation or registration issues (e.g., migrant status, no permanent registration)
C6_8	The clinic was too far away or appointments were hard to schedule
C6_9	I felt uncomfortable with the attitude of staff at the clinic
C6_10	I was worried that someone would find out I was taking PrEP
C6_11	I no longer felt at risk for HIV
C6_12	I switched to another way of preventing HIV
C6_13	I paused temporarily and plan to restart

Each option: 1 = Selected, 0 = Not selected. If no option was selected, all options carry the same missing code (-1 = Not shown (routing), -2 = Not reached, -9 = Not answered).

C7. In the past 6 months, how often have you used condoms during sex?

Variable: A_7 Single choice

Code	Response
1	Always
2	Most of the time
3	Sometimes
4	Rarely or never
5	No anal/vaginal intercourse in past 6 months

Code	Response
-2	*Not reached*
-9	*Not answered*

Note. *Exported by Qualtrics under the name A_7 (the item label C7 was typed with a Cyrillic letter). The variable name A_7 is kept in the data.*

STI1. When did you last get tested for sexually transmitted infections (STIs) other than HIV (e.g., syphilis, gonorrhoea, chlamydia)?

Variable: STI1 Single choice

Code	Response
1	Within the past 6 months
2	7–12 months ago
3	More than 1 year ago
4	I have never been tested for STIs
5	I don't remember
-2	*Not reached*
-9	*Not answered*

STI2. In the past 12 months, have you been diagnosed with any STI?

Variable: STI2_ Single choice

Code	Response
1	Yes
2	No
-2	*Not reached*
-9	*Not answered*

Note. *Variable name carries a trailing underscore (STI2_).*

[If STI2_=1 (diagnosed with an STI in the past 12 months)]

STI2a. Which STI(s) were you diagnosed with? (Select all that apply)

Variables: STI2a_1 to STI2a_9 (9) Multiple response

Variable	Option
STI2a_1	Syphilis
STI2a_2	Gonorrhoea
STI2a_3	Chlamydia
STI2a_4	Hepatitis C
STI2a_5	Hepatitis B
STI2a_6	Herpes (HSV-1 or HSV-2)
STI2a_7	HPV (human papillomavirus) or genital warts
STI2a_8	Mpox
STI2a_9	Other: (please specify)

Each option: 1 = Selected, 0 = Not selected. If no option was selected, all options carry the same missing code (-1 = Not shown (routing), -2 = Not reached, -9 = Not answered).

Note. *The free-text field STI2a_9_TEXT is withheld from the release file.*

[If STI1 is not 5 (I don't remember)]

STI3. Where do you usually get tested for STIs? (Select all that apply)

Variable: STI3 Single choice

Code	Response
1	HIV/AIDS centre or specialised clinic
2	Public polyclinic
3	Private clinic
4	Community-based organisation
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

Note. *Worded as select-all-that-apply but programmed and exported as a single-choice item.*

STI4. What are the main reasons you have not tested for STIs more regularly? (Select all that apply)

Variables: STI4_1 to STI4_8 (8) Multiple response

Variable	Option
STI4_1	I don't know where to get tested
STI4_2	I don't feel at risk
STI4_3	Cost
STI4_4	Fear of stigma or judgement
STI4_5	Concerns about confidentiality
STI4_6	Inconvenient hours or location
STI4_7	No particular reason
STI4_8	I test regularly — no barriers

Each option: 1 = Selected, 0 = Not selected. If no option was selected, all options carry the same missing code (-2 = Not reached, -9 = Not answered).

8.4 Block D. Educational materials about lenacapavir

Respondents read that lenacapavir is not currently available in Kazakhstan and that the survey asks about future planning. A structured information page then explained what lenacapavir is (a capsid inhibitor given as a subcutaneous injection every 6 months), its efficacy in the PURPOSE 1 and PURPOSE 2 trials, the initiation schedule (two injections plus two tablets on day 1, two tablets on day 2, two injections every 6 months with an HIV test before each), oral bridging if an injection is delayed by more than 2 weeks, common side effects including injection-site nodules, and that it does not protect against other STIs or pregnancy. No responses were recorded.

8.5 Block F. Acceptability and willingness to use

F1. Overall, how acceptable does lenacapavir seem to you as an HIV prevention option?

Variable: F1 Single choice

Code	Response
1	Very acceptable
2	Somewhat acceptable
3	Neither acceptable nor unacceptable
4	Somewhat unacceptable
5	Very unacceptable
-2	*Not reached*
-9	*Not answered*

F2. How willing would you be to use lenacapavir if it became available in Kazakhstan?

Variable: F2 Single choice

Code	Response
1	Very willing
2	Somewhat willing
3	Undecided
4	Somewhat unwilling
5	Very unwilling
-2	*Not reached*
-9	*Not answered*

F2a. If lenacapavir became available in Kazakhstan but was not covered free of charge, how much would you be willing to pay out-of-pocket per injection (once every 6 months)?

Variable: F2a Single choice

Code	Response
1	I would not use it unless it is completely free
2	Up to 5,000 KZT
3	5,001–15,000 KZT
4	15,001–30,000 KZT
5	30,001–50,000 KZT
6	More than 50,000 KZT
-2	*Not reached*
-9	*Not answered*

F2b. If lenacapavir became available in Kazakhstan with a 50% government, how much would you be willing to pay for your share per injection (once every 6 months)?

Variable: F2b Single choice

Code	Response
1	I would not use it unless it is completely free
2	Up to 2,500 KZT

Code	Response
3	2,501–7,500 KZT
4	7,501–15,000 KZT
5	15,001–25,000 KZT
6	More than 25,000 KZT
-2	*Not reached*
-9	*Not answered*

Note. *Wording as displayed in the English version, which omits the word subsidy after 50% government.*

F3. On a scale from 1 to 10, where 1 is “definitely would NOT use” and 10 is “definitely WOULD use”. How likely would you be to use lenacapavir?

Variable: F3_1 Slider, 1 to 10

Value	Anchor
1	Definitely would NOT use
2 to 9	Intermediate values, no labels
10	Definitely WOULD use
-2	*Not reached*
-9	*Not answered*

Integer values from 1 to 10.

F4. If all of the following PrEP options were available, which would you most prefer? (Select only one)

Variable: F4 Single choice

Code	Response
1	Daily oral PrEP (a pill taken every day)
2	On-demand (event-driven) oral PrEP (pills taken around the time of sex)
3	Injectable PrEP with cabotegravir (CAB-LA, injection every 2 months)
4	Twice-yearly injectable lenacapavir (injection every 6 months)
5	No preference — all are equally good options
6	I would not use any of these
-2	*Not reached*
-9	*Not answered*

F5. How important is each of the following in your decision about whether to use lenacapavir?

Variables: F5_1 to F5_4 (4) Grid [Importance response set, Section 6.2]

Variable	Item
F5_1	How well it prevents HIV
F5_2	Possible side effects
F5_3	How often I would need to visit a clinic
F5_4	Cost

Response codes for every item: 1 = Not at all important, 2 = Slightly important, 3 = Moderately important, 4 = Very important, 5 = Extremely important. Missing codes: -2 = Not reached, -9 = Not answered.

Q111. How important is each of the following in your decision about whether to use lenacapavir?

Variables: Q111_1 to Q111_4 (4) Grid [Importance response set, Section 6.2]

Variable	Item
Q111_1	What my friends or community think about it
Q111_2	Whether healthcare staff treat me with respect
Q111_3	Privacy and confidentiality
Q111_4	A recommendation from a doctor I trust

Response codes for every item: 1 = Not at all important, 2 = Slightly important, 3 = Moderately important, 4 = Very important, 5 = Extremely important. Missing codes: -2 = Not reached, -9 = Not answered.

Note. *Second page of the F5 grid. Qualtrics assigned the internal name Q111.*

F6. Which ONE of the factors listed above is the most important in deciding whether to use lenacapavir? (Select only one)

Variable: F6 Single choice

Code	Response
1	How well it prevents HIV
4	Possible side effects
5	How often I would need to visit a clinic
6	Cost
7	What my friends or community think about it
8	Whether healthcare staff treat me with respect
9	Privacy and confidentiality
10	A recommendation from a doctor I trust
-2	*Not reached*
-9	*Not answered*

8.6 Block G. Perceived benefits

G1. How important would each of these benefits be to you?

Variables: G1_1 to G1_4 (4) Grid [Importance response set, Section 6.2]

Variable	Item
G1_1	Not having to remember to take pills every day or around sex
G1_2	Only needing to think about HIV prevention twice a year
G1_3	No daily pills that others might notice (greater privacy)
G1_4	Very high effectiveness (nearly 100% in clinical studies)

Response codes for every item: 1 = Not at all important, 2 = Slightly important, 3 = Moderately important, 4 = Very important, 5 = Extremely important. Missing codes: -2 = Not reached, -9 = Not answered.

Q112. How important would each of these benefits be to you?

Variables: Q112_1 to Q112_4 (4) Grid [Importance response set, Section 6.2]

Variable	Item
Q112_1	Not having to worry about missed doses or timing pills around sex
Q112_2	Long-lasting protection between clinic visits

Variable	Item
Q112_3	Fewer interactions with other medications compared to daily pills
Q112_4	A better overall quality of life

Response codes for every item: 1 = Not at all important, 2 = Slightly important, 3 = Moderately important, 4 = Very important, 5 = Extremely important. Missing codes: -2 = Not reached, -9 = Not answered.

Note. *Second page of the G1 grid. Qualtrics assigned the internal name Q112.*

G2. Which ONE benefit from the list above would matter most to you? (Select only one)

Variable: G2 Single choice

Code	Response
1	Not having to remember to take pills every day or around sex
2	Only needing to think about HIV prevention twice a year
3	No daily pills that others might notice (greater privacy)
4	Very high effectiveness (nearly 100% in clinical studies)
5	Not having to worry about missed doses or timing pills around sex
6	Long-lasting protection between clinic visits
7	Fewer interactions with other medications compared to daily pills
8	A better overall quality of life
-2	*Not reached*
-9	*Not answered*

8.7 Block H. Concerns and barriers

H1. How concerned are you about each of the following?

Variables: H1_1 to H1_4 (4) Grid [Concern response set, Section 6.2]

Variable	Item
H1_1	Pain or discomfort from the injection
H1_2	Side effects from the medication (including nodules under the skin at the injection site)
H1_3	Having to go to a clinic every 6 months
H1_4	What might happen if I miss an appointment

Response codes for every item: 1 = Not at all concerned, 2 = Slightly concerned, 3 = Moderately concerned, 4 = Very concerned, 5 = Extremely concerned. Missing codes: -2 = Not reached, -9 = Not answered.

Q110. How concerned are you about each of the following?

Variables: Q110_1 to Q110_4 (4) Grid [Concern response set, Section 6.2]

Variable	Item
Q110_1	That it might not work as well as studies show
Q110_2	Cost or affordability
Q110_3	People at the clinic judging me or finding out about my HIV prevention
Q110_4	Not being able to stop immediately if I want to

Response codes for every item: 1 = Not at all concerned, 2 = Slightly concerned, 3 = Moderately concerned, 4 = Very concerned, 5 = Extremely concerned. Missing codes: -2 = Not reached, -9 = Not answered.

Note. *Second page of the H1 grid. Qualtrics assigned the internal name Q110.*

H2. Which ONE concern from the list above worries you most? (Select only one)

Variable: H2 Single choice

Code	Response
1	Pain or discomfort from the injection
2	Side effects from the medication (including nodules under the skin at the injection site)
3	Having to go to a clinic every 6 months
4	What might happen if I miss an appointment
5	That it might not work as well as studies show
6	Cost or affordability
7	People at the clinic judging me or finding out about my HIV prevention
8	Not being able to stop immediately if I want to
-2	*Not reached*
-9	*Not answered*

H3. If your injection is delayed, you can take weekly tablets to stay protected until the next injection. Does this make you less worried about missing an appointment?

Variable: H3 Single choice

Code	Response
1	Yes, a lot — it’s very reassuring
4	Yes, somewhat
5	No, it doesn’t change my concern
6	I’m not sure
-2	*Not reached*
-9	*Not answered*

8.8 Block I. Administration preferences

I1. If lenacapavir became available, where would you prefer to receive the injection?

Variable: I1 Single choice

Code	Response
1	AIDS Centre / specialised HIV clinic
4	Regular public clinic / polyclinic
5	Regular private clinic/ polyclinic
6	Community-based organisation
8	Mobile / outreach clinic
10	No preference
11	Key population–friendly room
-2	*Not reached*
-9	*Not answered*

I2. What makes a location feel safe and comfortable for receiving HIV prevention services? (Select all that apply)

Variables: I2_1 to I2_7 (5) Multiple response

Variable	Option
I2_1	Privacy — not being seen entering or leaving
I2_4	Friendly, non-judgmental staff who understand my community
I2_5	Clean, professional facility
I2_6	Convenient location with flexible hours (evenings/weekends)
I2_7	Other services available at same location

Each option: 1 = Selected, 0 = Not selected. If no option was selected, all options carry the same missing code (-2 = Not reached, -9 = Not answered).

I3. Who would you prefer to give you the injection?

Variables: I3_1 to I3_7 (4) Multiple response

Variable	Option
I3_1	Doctor
I3_4	Nurse
I3_6	Peer outreach worker (if trained)
I3_7	No preference

Each option: 1 = Selected, 0 = Not selected. If no option was selected, all options carry the same missing code (-2 = Not reached, -9 = Not answered).

Note. *Worded as a single question but programmed as select-all-that-apply.*

I4. What type of appointment scheduling would work best for you?

Variable: I4 Single choice

Code	Response
1	Scheduled appointments at specific times
4	Walk-in hours where I can come anytime
5	Both options available
6	No preference
-2	*Not reached*
-9	*Not answered*

I5. How would you prefer to receive appointment reminders?

Variable: I5 Single choice

Code	Response
1	SMS / text message
4	Phone call
5	Mobile app notification
6	I don’t want reminders
7	No preference
-2	*Not reached*
-9	*Not answered*

8.9 Block J. Healthcare experiences and stigma

J1. How much do you agree or disagree with the following statements?

Variables: J1_1 to J1_4 (4) Grid [Agreement response set, Section 6.2]

Variable	Item
J1_1	I trust healthcare providers to give me good medical care
J1_2	Healthcare providers treat me with respect
J1_3	I feel comfortable talking to healthcare providers about HIV prevention
J1_4	Healthcare facilities in my area are welcoming to people like me

Response codes for every item: 1 = Strongly disagree, 2 = Disagree, 3 = Neither agree nor disagree, 4 = Agree, 5 = Strongly agree. Missing codes: -2 = Not reached, -9 = Not answered.

J2. In the past 12 months, have you avoided seeking healthcare because of concerns about how you would be treated?

Variable: J2 Single choice

Code	Response
1	Yes, multiple times
4	Yes, once
5	No
-2	*Not reached*
-9	*Not answered*

J3. In the past 12 months, have you experienced any of the following?

Variables: J3_1 to J3_12 (12) Grid [Experience response set, Section 6.2]

Variable	Item
J3_1	Verbal harassment or insults because of your sexual orientation †
J3_2	Verbal harassment or insults because of drug use †
J3_3	Verbal harassment or insults because of sex work †
J3_4	Verbal harassment or insults because of gender identity †
J3_5	Physical violence because of your sexual orientation †
J3_6	Physical violence because of drug use †
J3_7	Physical violence because of sex work †
J3_8	Physical violence because of gender identity †
J3_9	Discrimination or denial of services in healthcare settings because of your sexual orientation †
J3_10	Discrimination or denial of services in healthcare settings because of drug use †
J3_11	Discrimination or denial of services in healthcare settings because of sex work †
J3_12	Discrimination or denial of services in healthcare settings because of gender identity †

Response codes for every item: 1 = Yes, 2 = No, 3 = Prefer not to answer. Missing codes: -1 = Not shown (routing), -2 = Not reached, -9 = Not answered.

† Row shown if A4_1=1 (GBMSM).

† Row shown if A4_2=1 (people who use drugs).

† Row shown if A4_3=1 (sex workers).

† Row shown if A4_4=1 (transgender people).

Note. *Each row was shown only to respondents who selected the matching key population at A4.*

J4. How much do you worry about stigma or discrimination when accessing healthcare services?

Variable: J4 Single choice

Code	Response
1	Not at all
4	A little
5	Somewhat
6	Quite a bit
7	Very much
-2	*Not reached*
-9	*Not answered*

8.10 Block K. Population-specific questions

[If A4_1=1 (GBMSM)]

K-MSM1. How do you primarily identify your sexual orientation?

Variable: K_MSM1 Single choice

Code	Response
1	Gay
4	Bisexual
5	Heterosexual / Straight
6	Other: (please specify)
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

Note. *The free-text field K_MSM1_6_TEXT is withheld from the release file.*

[If A4_1=1 or A4_4=1 (GBMSM or transgender)]

K-MSM2. In the past 3 months, approximately how many male sex partners have you had?

Variable: K_MSM2 Single choice

Code	Response
1	0
4	1
5	2–5
6	6–10
7	More than 10
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

[If A4_1=1 or A5=1 (GBMSM)]

Q108. In the past 3 months, how often have you met sexual partners through dating or hookup apps (e.g., Hornet, Grindr, Romeo, Tinder)?

Variable: Q108 Single choice

Code	Response
1	Never
2	Occasionally
3	Often
4	Almost always
5	I have not had any sexual partners in the past 3 months
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

Note. *Qualtrics assigned the internal name Q108.*

[If A4_1=1 or A4_4=1 (GBMSM or transgender)]

Q105. Some people use the term "chemsex" to describe the intentional use of certain drugs (such as mephedrone, Alpha-PHP or GHB/GBL) to enhance or prolong sex, often during longer sessions or with multiple partners. In the past 12 months, have you taken part in chemsex?

Variable: Q105 Single choice

Code	Response
1	Yes
2	No
3	I am not sure what the term means
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

Note. *Chemsex screener. Qualtrics assigned the internal name Q105.*

[If Q105=1 or Q105=3 (chemsex yes, or unsure what the term means)]

K-MSM3. In the past 12 months, have you used any of the following substances during or shortly before sex? (Select all that apply)

Variables: K_MSM3_4 to K_MSM3_11 (9) Multiple response

Variable	Option
K_MSM3_4	Mephedrone or other synthetic cathinones
K_MSM3_8	Alpha-PHP (Speed)
K_MSM3_5	GHB / GBL
K_MSM3_10	Erectile dysfunction medications (Viagra, Cialis) used recreationally
K_MSM3_9	Poppers (amyl nitrite)
K_MSM3_1	Methamphetamine (crystal meth, ice)
K_MSM3_7	MDMA / ecstasy
K_MSM3_6	Cocaine

Variable	Option
K_MSM3_11	Other substances: (please specify)

Each option: 1 = Selected, 0 = Not selected. If no option was selected, all options carry the same missing code (-1 = Not shown (routing), -2 = Not reached, -9 = Not answered).

Note. *The free-text field K_MSM3_11_TEXT is withheld from the release file.*

[If Q105=1 or Q105=3]

K-MSM4. In the past 12 months, approximately how often have you taken part in chemsex sessions?

Variable: K_MSM4 Single choice

Code	Response
1	Once or twice in the past year
4	Every few months
5	About once a month
6	Two or three times a month
7	Once a week or more often
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

[If Q105=1 or Q105=3]

K-MSM5. In the past 12 months, have any of the following happened during or after chemsex? (Select all that apply.)

Variables: K_MSM5_1 to K_MSM5_9 (6) Multiple response

Variable	Option
K_MSM5_1	I had condomless sex that I would not have had otherwise
K_MSM5_4	I missed a dose of PrEP because of chemsex
K_MSM5_5	I had sex with more partners than I had planned
K_MSM5_6	I had sex with someone whose HIV status I did not know
K_MSM5_8	I felt unable to stop the session when I wanted to
K_MSM5_9	I experienced low mood, anxiety, or exhaustion afterwards ("come-down")

Each option: 1 = Selected, 0 = Not selected. If no option was selected, all options carry the same missing code (-1 = Not shown (routing), -2 = Not reached, -9 = Not answered).

Note. *The exclusive option 'None of the above' (code 10) was not exported by Qualtrics. Respondents who chose it appear with no option selected and are coded -9.*

[If A4_1=1 (GBMSM)]

K-MSM6. Lenacapavir provides continuous protection without needing to remember pills (daily or around sexual encounters). How important is that to you in the context of sexual situations where you might not plan ahead?

Variable: K_MSM6 Single choice

Code	Response
1	Extremely important
4	Very important

Code	Response
5	Moderately important
6	Slightly important
7	Not at all important
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

Note. *Codes run in reverse order (1 = Extremely important, 7 = Not at all important).*

[If A4_1=1 (GBMSM)]

K-MSM7. How important is privacy about using HIV prevention to you?

Variable: K_MSM7 Single choice

Code	Response
1	Not at all important
4	Slightly important
5	Moderately important
6	Very important
7	Extremely important
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

[If A4_1=1 (GBMSM)]

K-MSM8. Would injectable lenacapavir make it easier to keep your HIV prevention private?

Variable: K_MSM8 Single choice

Code	Response
1	Yes, I would be more comfortable because there are no pills to take
4	No, it wouldn’t make a difference
5	I’m not sure
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

[If A4_2=1 (people who use drugs)]

K-PWUD1. What substance(s) have you used in the past 12 months? (Select all that apply)

Variables: K_PWUD1_1 to K_PWUD1_8 (7) Multiple response

Variable	Option
K_PWUD1_1	Heroin
K_PWUD1_4	Other opioids (Methadone, Fentanyl)
K_PWUD1_5	Mephedrone or other synthetic cathinones (3-MMC, 4-MMC)
K_PWUD1_6	Alpha-PHP (Speed)

Variable	Option
K_PWUD1_7	Methamphetamine
K_PWUD1_10	Marijuana (cannabis, buds, center, ganja)
K_PWUD1_8	Other: (please specify)

Each option: 1 = Selected, 0 = Not selected. If no option was selected, all options carry the same missing code (-1 = Not shown (routing), -2 = Not reached, -9 = Not answered).

Note. *The free-text field K_PWUD1_8_TEXT is withheld from the release file.*

[If A4_2=1]

K-PWUD1b. How do you primarily use these substances? (Select all that apply)

Variables: K_PWUD1b_1 to K_PWUD1b_6 (4) Multiple response

Variable	Option
K_PWUD1b_1	Injecting
K_PWUD1b_4	Smoking or inhaling
K_PWUD1b_5	Snorting
K_PWUD1b_6	Swallowing

Each option: 1 = Selected, 0 = Not selected. If no option was selected, all options carry the same missing code (-1 = Not shown (routing), -2 = Not reached, -9 = Not answered).

[If A4_2=1]

K-PWUD2. In the past month, how often have you used drugs?

Variable: K_PWUD2 Single choice

Code	Response
1	Daily or almost daily
4	3–6 times per week
5	1–2 times per week
6	Less than once per week
7	Not at all in the past month
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

[If A4_2=1]

K-PWUD3. Do you currently access harm reduction services (needle exchange, etc.) or substance use treatment?

Variable: K_PWUD3 Single choice

Code	Response
1	Yes, harm reduction services
4	Yes, medication-assisted treatment (MAT) and/or counselling
5	Yes, both
6	No, not currently
-1	*Not shown (routing)*

Code	Response
-2	*Not reached*
-9	*Not answered*

K-PWUD4. How comfortable are you with receiving medical injections?

Variable: K_PWUD4 Single choice

Code	Response
1	Very comfortable
4	Somewhat comfortable
5	Neutral
6	Somewhat uncomfortable
7	Very uncomfortable
-2	*Not reached*
-9	*Not answered*

K-PWUD5. How confident are you that you could keep track of appointments every 6 months?

Variable: K_PWUD5 Single choice

Code	Response
1	Very confident
4	Somewhat confident
5	Neutral
6	Somewhat doubtful
7	Very doubtful
-2	*Not reached*
-9	*Not answered*

[If A4_3=1 (sex workers)]

K-SW2. In the past 3 months, how many clients have you had on average per week?

Variable: K_SW2 Single choice

Code	Response
1	0–2
4	3–5
5	6–10
6	More than 10
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

[If A4_3=1]

K-SW3. Do you travel to other cities for sex work?

Variable: K_SW3 Single choice

Code	Response
1	Yes, frequently (weekly/monthly)
4	Yes, occasionally (few times per year)
5	No, I work only in one location
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

K-SW4. How flexible is your work schedule for attending healthcare appointments?

Variable: K_SW4 Single choice

Code	Response
1	Very flexible — I can make time
4	Somewhat flexible
5	Not very flexible
6	Not flexible at all
-2	*Not reached*
-9	*Not answered*

[If A4_3=1]

K-SW5. How important is it that clients don’t know you’re using HIV prevention?

Variable: K_SW5 Single choice

Code	Response
1	Not at all important
4	Slightly important
5	Moderately important
6	Very important
7	Extremely important
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

[If A4_4=1 (transgender people)]

K-TW1. Are you currently taking gender-affirming hormones (feminising or masculinising)?

Variable: K_TW1 Single choice

Code	Response
1	Yes, prescribed by a doctor
4	Yes, obtained without prescription
5	No, but I would like to
6	No, and I don’t plan to

Code	Response
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

[If A4_4=1 (transgender people)]

K-TW2. How concerned are you about possible interactions between lenacapavir and hormone therapy?

Variable: K_TW2 Single choice

Code	Response
1	Not at all concerned
4	Slightly concerned
5	Moderately concerned
6	Very concerned
7	Extremely concerned
8	Not applicable (not taking hormones)
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

Note. *Code 8 (Not applicable, not taking hormones) is not part of the concern scale.*

[If A4_4=1 (transgender people)]

K-TW3. Have you experienced difficulties accessing healthcare due to documentation or gender marker issues?

Variable: K_TW3 Single choice

Code	Response
1	Yes, frequently
4	Yes, occasionally
5	No
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

[If A4_4=1 (transgender people)]

K-TW4. How important is it that healthcare providers are knowledgeable about transgender health?

Variable: K_TW4 Single choice

Code	Response
1	Not at all important
4	Slightly important
5	Moderately important
6	Very important
7	Extremely important
-1	*Not shown (routing)*

Code	Response
-2	*Not reached*
-9	*Not answered*

[If A4_4=1 (transgender people)]

K-TW5. Would you prefer to receive lenacapavir services at a facility that specialises in gender-affirming care?

Variable: K_TW5 Single choice

Code	Response
1	Yes, definitely prefer
4	Somewhat prefer
5	No preference
6	Prefer general facility
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

8.11 Block K2. Mental health

K2-2. Over the last 2 weeks, how often have you been bothered by the following problems?

Variables: K2_2_1 to K2_2_4 (4) Grid [PHQ-4 frequency response set, Section 6.2]

Variable	Item
K2_2_1	Feeling nervous, anxious, or on edge
K2_2_2	Not being able to stop or control worrying
K2_2_3	Little interest or pleasure in doing things
K2_2_4	Feeling down, depressed, or hopeless

Response codes for every item: 1 = Not at all, 2 = Several days, 3 = More than half the days, 4 = Nearly every day. Missing codes: -2 = Not reached, -9 = Not answered.

Note. *PHQ-4. Items 1 and 2 form the GAD-2, items 3 and 4 the PHQ-2. Codes 1 to 4 correspond to scores 0 to 3; see the derived variables in Section 9.*

8.12 Block K-8. Perceptions of PrEP

[If A4_1=1 (GBMSM)]

K-PFB8.1 (Q1–10). How important is each of the following in supporting your use of <PrEP type from C3a>?

Variables: K_PFB8.1__Q1_10__1 to K_PFB8.1__Q1_10__12 (12) Grid [Importance response set, Section 6.2]

Variable	Item
K_PFB8.1__Q1_10__1	Being able to take PrEP without it being linked to specific sexual activity †
K_PFB8.1__Q1_10__2	Being able to take PrEP only around the times I have sex †
K_PFB8.1__Q1_10__3	Not needing injections or clinic procedures
K_PFB8.1__Q1_10__4	Feeling that PrEP is accepted or used within my social or sexual network
K_PFB8.1__Q1_10__5	Having PrEP available at clinics or pharmacies that are affirming toward gay and bisexual men
K_PFB8.1__Q1_10__6	Flexible clinic hours that fit around my lifestyle
K_PFB8.1__Q1_10__7	No cost

Variable	Item
K_PFB8.1__Q1_10__8	Healthcare providers who are non-judgmental about sex between men
K_PFB8.1__Q1_10__9	Clear information about how PrEP works with condom use and other STI prevention
K_PFB8.1__Q1_10__10	Ability to maintain PrEP use discreetly without others knowing †
K_PFB8.1__Q1_10__11	Ability to time PrEP use discreetly around sexual encounters †
K_PFB8.1__Q1_10__12	Feeling in control of my HIV prevention without depending on a partner

Response codes for every item: 1 = Not at all important, 2 = Slightly important, 3 = Moderately important, 4 = Very important, 5 = Extremely important. Missing codes: -1 = Not shown (routing), -2 = Not reached, -9 = Not answered.

† Row shown only if C3a=1 (daily oral PrEP).

† Row shown only if C3a=2 (on-demand PrEP).

Note. *Question text pipes in the PrEP type selected at C3a. Respondents without a C3a answer saw the word 'PrEP'. Shown to all GBMSM, including those who had never used PrEP.*

[If A4_1=1 (GBMSM)]

K-PFB8.1 Q11. Which ONE factor above most supports your use of <PrEP type from C3a>?

Variable: K_PFB8.1_Q11 Single choice

Code	Response
1	Being able to take PrEP without it being linked to specific sexual activity
2	Being able to take PrEP only around the times I have sex
3	Not needing injections or clinic procedures
4	Feeling that PrEP is accepted or used within my social or sexual network
12	Feeling in control of my HIV prevention without depending on a partner
13	Having PrEP available at clinics or pharmacies that are affirming toward gay and bisexual men
14	Flexible clinic hours that fit around my lifestyle
15	No cost
16	Healthcare providers who are non-judgmental about sex between men
17	Clear information about how PrEP works with condom use and other STI prevention
18	Ability to maintain PrEP use discreetly without others knowing
19	Ability to time PrEP use discreetly around sexual encounters
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

Note. *Choices 1 and 18 were offered only if C3a=1, choices 2 and 19 only if C3a=2.*

[If C3=1 or C3=2 (current or past PrEP use)]

K-PFB8.2 (Q13–22). How much does each of the following make it difficult for you to use <PrEP type from C3a>?

Variables: K_PFB8.2__Q13_22__1 to K_PFB8.2__Q13_22__13 (13) Grid [Barrier response set, Section 6.2]

Variable	Item
K_PFB8.2__Q13_22__1	Having to remember to take a pill every day †
K_PFB8.2__Q13_22__2	Having to plan and time pill-taking around sexual activity †
K_PFB8.2__Q13_22__3	Fear of missing doses during periods of frequent or unplanned sex †
K_PFB8.2__Q13_22__4	Difficulty timing doses correctly when sex is spontaneous †

Variable	Item
K_PFB8.2__Q13_22__5	Fear that others will see my PrEP pills and make assumptions about my sexuality or behavior
K_PFB8.2__Q13_22__6	Concerns about confidentiality at healthcare facilities
K_PFB8.2__Q13_22__7	Concerns about side effects
K_PFB8.2__Q13_22__8	Reluctance to take medication long-term when HIV risk varies †
K_PFB8.2__Q13_22__9	Uncertainty about when my risk is high enough to use on-demand PrEP †
K_PFB8.2__Q13_22__10	Burden of clinic visits, lab tests, or prescription refills
K_PFB8.2__Q13_22__11	Stigma from healthcare providers related to sex between men
K_PFB8.2__Q13_22__12	Difficulty discussing sexual practices openly with a doctor or nurse
K_PFB8.2__Q13_22__13	Concerns about how PrEP interacts with recreational drug use (e.g., during chemsex)

Response codes for every item: 1 = Not at all a barrier, 2 = Slightly a barrier, 3 = Moderately a barrier, 4 = Very much a barrier, 5 = Extremely a barrier. Missing codes: -1 = Not shown (routing), -2 = Not reached, -9 = Not answered.

† Row shown only if C3a=1 (daily oral PrEP).

† Row shown only if C3a=2 (on-demand PrEP).

Note. *Question text pipes in the PrEP type selected at C3a. Respondents without a C3a answer (past users) saw the word 'PrEP'.*

[If C3=1 or C3=2]

K-PFB8.2 Q23. Which ONE barrier above affects you the most?

Variable: K_PFB8.2_Q23 Single choice

Code	Response
1	Having to remember to take a pill every day
2	Having to plan and time pill-taking around sexual activity
3	Fear of missing doses during periods of frequent or unplanned sex
4	Difficulty timing doses correctly when sex is spontaneous
5	Fear that others will see my PrEP pills and make assumptions about my sexuality or behavior
6	Concerns about confidentiality at healthcare facilities
7	Concerns about side effects
8	Reluctance to take medication long-term when HIV risk varies
9	Uncertainty about when my risk is high enough to use on-demand PrEP
10	Burden of clinic visits, lab tests, or prescription refills
11	Stigma from healthcare providers related to sex between men
12	Difficulty discussing sexual practices openly with a doctor or nurse
13	Concerns about how PrEP interacts with recreational drug use (e.g., during chemsex)
-1	*Not shown (routing)*
-2	*Not reached*
-9	*Not answered*

Note. *Choices 1, 3 and 8 were offered only if C3a=1, choices 2, 4 and 9 only if C3a=2.*

[If C3=1 or C3=2]

K-PFB8.3 Q25. What might prevent you from using <PrEP type from C3a> consistently? (Select all that apply)

Variables: K_PFB8.3_Q25_1 to K_PFB8.3_Q25_41 (14) Multiple response

Variable	Option
K_PFB8.3_Q25_1	Difficulty remembering daily medication †
K_PFB8.3_Q25_43	Difficulty timing pills correctly around sex †
K_PFB8.3_Q25_31	Inconsistent daily routine †
K_PFB8.3_Q25_44	Spontaneous or unpredictable sexual activity †
K_PFB8.3_Q25_32	Clinic or pharmacy is too far away
K_PFB8.3_Q25_33	Clinic hours do not fit my schedule
K_PFB8.3_Q25_34	Concerns about privacy or confidentiality at healthcare facilities
K_PFB8.3_Q25_35	Fear of being identified as gay or bisexual when seeking PrEP
K_PFB8.3_Q25_36	Negative or discriminatory past experiences with healthcare providers
K_PFB8.3_Q25_37	Criminalization of same-sex behavior in my country making me hesitant to seek services
K_PFB8.3_Q25_38	Housing instability or lack of a safe place to store medication
K_PFB8.3_Q25_39	Travel or mobility issues
K_PFB8.3_Q25_40	Prefer a different HIV prevention method (e.g., long-acting injectable)
K_PFB8.3_Q25_41	Nothing would prevent me

Each option: 1 = Selected, 0 = Not selected. If no option was selected, all options carry the same missing code (-1 = Not shown (routing), -2 = Not reached, -9 = Not answered).

† Choice shown only if C3a=1. Coded -1 for respondents to whom the option was not shown.

† Choice shown only if C3a=2. Coded -1 for respondents to whom the option was not shown.

8.13 Block L. Decision-making and information

L1. If lenacapavir became available, what information would you want before deciding whether to use it? (Select all that apply)

Variables: L1_1 to L1_10 (8) Multiple response

Variable	Option
L1_1	More details about how well it works
L1_4	Complete list of side effects
L1_5	Experiences of other people who have used it
L1_6	Cost information
L1_7	Where and how to access it
L1_8	Drug interaction information
L1_9	Long-term safety data
L1_10	Comparison with other PrEP options (daily oral, on-demand, injectable cabotegravir)

Each option: 1 = Selected, 0 = Not selected. If no option was selected, all options carry the same missing code (-2 = Not reached, -9 = Not answered).

L2. Where would you want to get information about lenacapavir? (Select all that apply)

Variables: L2_1 to L2_7 (5) Multiple response

Variable	Option
L2_1	Healthcare providers
L2_4	Community organisations
L2_5	Friends or peers
L2_6	Online / social media
L2_7	Educational materials / brochures

Each option: 1 = Selected, 0 = Not selected. If no option was selected, all options carry the same missing code (-2 = Not reached, -9 = Not answered).

L3. Would you discuss using lenacapavir with anyone before deciding?

Variables: L3_1 to L3_7 (5) Multiple response

Variable	Option
L3_1	Yes, with partner(s)
L3_4	Yes, with friends
L3_5	Yes, with healthcare provider
L3_6	Yes, with family
L3_7	No, this would be my personal decision

Note. *Worded as a single question but programmed as select-all-that-apply. L3_7 (No, this would be my personal decision) was not exclusive.*

Each option: 1 = Selected, 0 = Not selected. If no option was selected, all options carry the same missing code (-2 = Not reached, -9 = Not answered).

8.14 Block M. Final questions

M2. If lenacapavir becomes available in Kazakhstan, would you be interested in learning more about it?

Variable: M2 Single choice

Code	Response
1	Yes, definitely
4	Probably yes
5	Not sure
6	Probably not
7	Definitely not
-2	*Not reached*
-9	*Not answered*

9. Derived Variables

The following variables were created by the study team. They follow the definitions used in the study's own analyses so that results can be compared.

KP_N. Number of key populations

Count of A4_1 to A4_4 equal to 1.

Code	Label
1	One
2	Two
3	Three
4	Four

KP_GROUP. Hierarchical key population group

Mutually exclusive grouping used in the study analyses. Transgender people (A4_4=1) first, then GBMSM (A4_1=1), then everyone else, who are people who use drugs or sex workers only.

Code	Label
1	Transgender people
2	GBMSM (not transgender)
3	People who use drugs or sex workers only

CIS_GBMSM. Cisgender GBMSM analytic definition

1 if A4_1=1 and A4_4 is not selected and B1=1 (man) and B2=1 (male). Respondents with B1 missing are coded 0. GBMSM who also use drugs or sell sex are included.

Code	Label
0	No
1	Yes

GAD2, PHQ2, PHQ4. PHQ-4 scores

Items K2_2_1 to K2_2_4 are scored 0 to 3 (code minus 1). GAD2 is the sum of K2_2_1 and K2_2_2, PHQ2 the sum of K2_2_3 and K2_2_4, and PHQ4 the sum of all four. A score is computed only when all its items were answered. Otherwise it takes -2 if any item was not reached and -9 if items were skipped.

Score	Range	Missing codes
GAD2	0 to 6	-2, -9
PHQ2	0 to 6	-2, -9
PHQ4	0 to 12	-2, -9

GAD2_POS. Positive GAD-2 screen

1 if GAD2 is 3 or higher.

Code	Label
0	No
1	Yes
-2	Not reached
-9	Not answered

PHQ2_POS. Positive PHQ-2 screen

1 if PHQ2 is 3 or higher.

Code	Label
0	No
1	Yes
-2	Not reached
-9	Not answered

PHQ4_CAT. PHQ-4 severity

Standard PHQ-4 categories of psychological distress.

Code	Label
1	Normal (0 to 2)
2	Mild (3 to 5)
3	Moderate (6 to 8)
4	Severe (9 to 12)
-2	Not reached
-9	Not answered

10. City and Region Response Set (A3)

A3 asked respondents to select their city of residence from a list of cities of republican significance and regional centres. Regional centres are labelled together with their region. Code 26 (outside Kazakhstan) ended the survey and does not occur in the release file. Codes 19 to 23 were not used.

Code	City / region
1	Almaty
2	Astana
3	Shymkent
4	Aktobe / Aktobe Region
5	Aktau / Mangystau Region
6	Atyrau / Atyrau Region
7	Zhezkazgan / Ulytau Region
8	Karaganda / Karaganda Region
9	Kokshetau / Akmola Region
10	Konaev / Almaty Region
11	Kostanay / Kostanay Region
12	Kyzylorda / Kyzylorda Region
13	Pavlodar / Pavlodar Region
14	Petropavl / North Kazakhstan Region
15	Semey / Abai Region
16	Taldykorgan / Zhetysu Region
17	Taraz / Zhambyl Region
18	Turkistan / Turkistan Region
24	Uralsk / West Kazakhstan Region
25	Ust-Kamenogorsk / East Kazakhstan Region

11. Routing Summary

Table 11.1 lists every question with a display condition. Respondents who did not meet the condition are coded -1 on all variables of the question.

Question	Display condition
A5	Two or more key populations were selected at A4
C2a	C2=1 or C2=3 (heard of PrEP or not sure)
C3a	C3=1 (currently using PrEP)
C4	C3=1 or C3=2 (current or past PrEP use)
C5	C3a=1 or C3a=2
C6	C3=2 (used PrEP in the past)
STI2a	STI2_=1 (diagnosed with an STI in the past 12 months)
STI3	STI1 is not 5 (I don't remember)
K-MSM1	A4_1=1 (GBMSM)
K-MSM2	A4_1=1 or A4_4=1 (GBMSM or transgender)
Q108	A4_1=1 or A5=1 (GBMSM)
Q105	A4_1=1 or A4_4=1 (GBMSM or transgender)
K-MSM3	Q105=1 or Q105=3 (chemsex yes, or unsure what the term means)
K-MSM4	Q105=1 or Q105=3
K-MSM5	Q105=1 or Q105=3
K-MSM6	A4_1=1 (GBMSM)
K-MSM7	A4_1=1 (GBMSM)
K-MSM8	A4_1=1 (GBMSM)
K-PWUD1	A4_2=1 (people who use drugs)
K-PWUD1b	A4_2=1
K-PWUD2	A4_2=1
K-PWUD3	A4_2=1
K-SW2	A4_3=1 (sex workers)
K-SW3	A4_3=1
K-SW5	A4_3=1
K-TW1	A4_4=1 (transgender people)
K-TW2	A4_4=1 (transgender people)
K-TW3	A4_4=1 (transgender people)
K-TW4	A4_4=1 (transgender people)
K-TW5	A4_4=1 (transgender people)
K-PFB8.1 (Q1-10)	A4_1=1 (GBMSM)
K-PFB8.1 Q11	A4_1=1 (GBMSM)
K-PFB8.2 (Q13-22)	C3=1 or C3=2 (current or past PrEP use)
K-PFB8.2 Q23	C3=1 or C3=2
K-PFB8.3 Q25	C3=1 or C3=2

Grid rows and options with their own display condition are marked with a dagger in Section 8. J3 rows were shown by key population.